<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240506061682N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-06-19</date_registration>
      <primary_sponsor>Yasouj University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of combined vaginal gel of oak placenta and fennel on sexual function and quality of sexual life of postmenopausal women</public_title>
      <acronym></acronym>
      <scientific_title>The effect of combined vaginal gel of Quercus brantii and fennel (Foeniculum vulgare) on the sexual function and quality of sexual life of  menopausal women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-07-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/76686</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: First, people will be randomly assigned to two groups of herbal gel and placebo by Computer Random Generation method. The tubes will be coded by the pharmacist using a table of random numbers and noted by the pharmacist, so that each tube has a unique code. Only the pharmacist knows which tube contains gel and which tube contains placebo. Researchers or volunteers participating in the project are covered, Blinding description: Both the menopausal women participating in the project and the researcher related to them are unaware of the exposure received, the tube and box of gel and placebo are offered in a completely similar appearance and packaging, and each has its own code, which is only the pharmacist of the mentioned items. knows.</study_design>
      <phase>3</phase>
      <hc_freetext>Quality of sexual life and sexual performance.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Each person received a 50-gram tube containing a combined herbal gel of oak (5.2%) and fennel (5%) with an applicator to be used for 8 weeks (one gram every night for the first two weeks, and the next six weeks every other night) will be given. Then the patient will be called to the health center through a phone call. The patient will be taught the duration of use and the follow-up times, and the patients will be asked to return for re-examination and follow-up in the eighth week from the start of treatment. The phone number of the patients will be taken and the method of use and follow-up times will be reminded and it will be emphasized that they should not use any hormonal drugs with other vaginal ingredients. In case of any complications (such as allergy ) after taking the medicine, the intervention will be stopped and complications will be reported. Questionnaires of the quality of sexual life and sexual performance are completed by people before and after the intervention. Intervention 2: Control group:  Each person will be given a 50 gram tube containing placebo with an applicator to be consumed for 8 weeks (one gram every night for the first two weeks, and every other night for the next six weeks). Then the patient will be called to the health center through a phone call. The patient will be taught the duration of use and the follow-up times, and the patients will be asked to return for re-examination and follow-up in the eighth week from the start of treatment. The phone number of the patients will be taken and the method of use and follow-up times will be reminded and it will be emphasized that they should not use any hormonal drugs with other vaginal ingredients. In case of any complications (such as allergy ) after taking the medicine, the intervention will be stopped and complications will be reported. Questionnaires of the quality of sexual life and sexual performance are completed by people before and after the intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The research results will be made available to everyone with honesty.

When:
The research results will be made available to everyone with honesty.

To whom:
The research results will be made available to everyone with honesty.

Conditions:
The research results will be made available to everyone with honesty.

Where to obtain:
The research results will be made available to everyone with honesty.

How to obtain:
The research results will be made available to everyone with honesty.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sara  Nikkhah</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Motahari Boulevard</address>
        <city>Yasuj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7591396661</zip>
        <telephone>+98 917 664 8896</telephone>
        <email>saranik358@gmail.com</email>
        <affiliation>Yasouj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sara Nikkhah</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Motahari Boulevard</address>
        <city>Yasuj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7591396661</zip>
        <telephone>+98 917 664 8896</telephone>
        <email>saranik358@gmail.com</email>
        <affiliation>Yasouj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Passing at least one year since the last menstruation, having a hormone test with an FSH level greater than 40 international units
age range of 45-65 years
having sex and being monogamous</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Each person received a 50-gram tube containing a combined herbal gel of oak (5.2%) and fennel (5%) with an applicator to be used for 8 weeks (one gram every night for the first two weeks, and the next six weeks every other night) will be given. Then the patient will be called to the health center through a phone call. The patient will be taught the duration of use and the follow-up times, and the patients will be asked to return for re-examination and follow-up in the eighth week from the start of treatment. The phone number of the patients will be taken and the method of use and follow-up times will be reminded and it will be emphasized that they should not use any hormonal drugs with other vaginal ingredients. In case of any complications (such as allergy ) after taking the medicine, the intervention will be stopped and complications will be reported. Questionnaires of the quality of sexual life and sexual performance are completed by people before and after the intervention.</i_keyword>
      <i_keyword>Control group:  Each person will be given a 50 gram tube containing placebo with an applicator to be consumed for 8 weeks (one gram every night for the first two weeks, and every other night for the next six weeks). Then the patient will be called to the health center through a phone call. The patient will be taught the duration of use and the follow-up times, and the patients will be asked to return for re-examination and follow-up in the eighth week from the start of treatment. The phone number of the patients will be taken and the method of use and follow-up times will be reminded and it will be emphasized that they should not use any hormonal drugs with other vaginal ingredients. In case of any complications (such as allergy ) after taking the medicine, the intervention will be stopped and complications will be reported. Questionnaires of the quality of sexual life and sexual performance are completed by people before and after the intervention.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Questionnaire score of sexual performance. Timepoint: At the beginning of the study and before drug administration and 8 weeks after the start of treatment. Method of measurement: Postmenopausal Women's Sexual Performance Questionnaire (FSFI).</prim_outcome>
      <prim_outcome>Quality of sexual life of menopausal women. Timepoint: At the beginning of the study and before drug administration and 8 weeks after the start of treatment. Method of measurement: Women's Quality of Life Questionnaire (SQOL-F).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Sexual desire. Timepoint: At the beginning of the study before drug administration and also after treatment. Method of measurement: Questionnaire of sexual function of postmenopausal women.</sec_outcome>
      <sec_outcome>Orgasm. Timepoint: At the beginning of the study before drug administration and also after treatment. Method of measurement: Questionnaire of sexual function of postmenopausal women.</sec_outcome>
      <sec_outcome>Stimulation. Timepoint: At the beginning of the study before drug administration and also after treatment. Method of measurement: Questionnaire of sexual function of postmenopausal women.</sec_outcome>
      <sec_outcome>Get wet. Timepoint: At the beginning of the study before drug administration and also after treatment. Method of measurement: Questionnaire of sexual function of postmenopausal women.</sec_outcome>
      <sec_outcome>Satisfaction. Timepoint: At the beginning of the study before drug administration and also after treatment. Method of measurement: Questionnaire of sexual function of postmenopausal women.</sec_outcome>
      <sec_outcome>The pain. Timepoint: At the beginning of the study before drug administration and also after treatment. Method of measurement: Questionnaire of sexual function of postmenopausal women.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yasouj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-04-27</approval_date>
        <contact_name>Ethics Committee of Yasouj University of Medical Sciences</contact_name>
        <contact_address>Qorani Blvd./ Shahid Dehrabpur St./ Corner of Jhanbazan 8 yasuj Kohgilouyeh-va-Boyrahmad Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
